Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Novartis delivered sales growth -5-

01/26/2021 | 01:01am EDT
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales            20.7    14.7                  20.9    19.2 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core operating income         3 501   3 462      1      2  15 416  14 112     9      13 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales            27.4    27.9                  31.7    29.7 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Net income                    2 099   1 129     86     93   8 071   7 147    13      20 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
EPS (USD)                      0.92    0.50     84     93    3.55    3.12    14      21 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core net income               3 034   2 985      2      3  13 158  12 104     9      12 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core EPS (USD)                 1.34    1.32      2      3    5.78    5.28     9      13 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Cash flows from 
 operating activities         4 005   3 540     13         13 650  13 547     1 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Free cash flow                3 342   3 488     -4         11 691  12 937   -10 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
 
                                 Q4      Q4                    FY      FY 
Innovative Medicines           2020    2019    % change      2020    2019    % change 
                              USD m   USD m    USD     cc   USD m   USD m   USD      cc 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Net sales                    10 233   9 920      3      1  39 013  37 714     3       4 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Operating income              2 386   2 210      8     12   9 172   9 287    -1       4 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales            23.3    22.3                  23.5    24.6 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core operating income         3 212   3 122      3      3  13 645  12 650     8      11 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales            31.4    31.5                  35.0    33.5 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
 
                                 Q4      Q4                    FY      FY 
Sandoz                         2020    2019     % change     2020    2019    % change 
                              USD m   USD m    USD     cc   USD m   USD m   USD      cc 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Net sales                     2 537   2 483      2      0   9 646   9 731    -1       0 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Operating income                372    -195     nm     nm   1 043     551    89     106 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales            14.7    -7.9                  10.8     5.7 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core operating income           528     517      2      3   2 334   2 094    11      15 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales            20.8    20.8                  24.2    21.5 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
 
                                 Q4      Q4                    FY      FY 
Corporate                      2020    2019    % change      2020    2019    % change 
                              USD m   USD m    USD     cc   USD m   USD m   USD      cc 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Operating loss                 -114    -192     41     45     -63    -752    nm      nm 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core operating loss            -239    -177    -35    -28    -563    -632    11      14 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
 
                                 Q4      Q4                    FY      FY 
Discontinued operations        2020    2019    % change      2020    2019    % change 
                              USD m   USD m    USD     cc   USD m   USD m   USD      cc 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Net sales                                                           1 777 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Operating income                                                       71 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales                                                   4.0 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core operating income                                                 350 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales                                                  19.7 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Net Income                                                          4 590 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
 
                                 Q4      Q4                    FY      FY 
Total Group                    2020    2019    % change      2020    2019    % change 
                              USD m   USD m    USD     cc   USD m   USD m   USD      cc 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Net income                    2 099   1 129     86     93   8 071  11 737   -31     -27 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
EPS (USD)                      0.92    0.50     84     93    3.55    5.12   -31     -26 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core net income               3 034   2 985      2      3  13 158  12 382     6       9 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core EPS (USD)                 1.34    1.32      2      3    5.78    5.40     7      10 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Cash flows 
 from operating activities    4 005   3 540     13         13 650  13 625     0 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Free cash flow                3 342   3 488     -4         11 691  12 875    -9 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
 
nm = not meaningful 
 
   (1) Continuing operations include the businesses of Innovative Medicines 
and Sandoz Division as well as the continuing corporate functions and 
discontinued operations include the business of Alcon. See page 43 of 
the Condensed Financial Report for full explanation. 
 
   (2) Constant currencies (cc), core results and free cash flow are 
non-IFRS measures. An explanation of non-IFRS measures can be found on 
page 55 of the Condensed Financial Report. Unless otherwise noted, all 
growth rates in this Release refer to same period in prior year. 
 
   Detailed financial results accompanying this press release are included 
in the Condensed Financial Report at the link below: 
 
   https://ml-eu.globenewswire.com/resource/download/62b8c900-3637-4459-a7a1-da6012d415b5/ 
 
 
   Disclaimer 
 
   This press release contains forward-looking statements within the 
meaning of the United States Private Securities Litigation Reform Act of 
1995, that can generally be identified by words such as "next wave," 
"transformative," "continuing," "progressing," "guidance," "will result, 
" "looking ahead," "confident," "progress," "to execute," "continue," 
"expect," "remains," "to maintain," "continues," "to evolve," "to take," 
"to help," "remain," "remains," "to grow," "continues," "to evolve," 
"continue," "to help," "remain," "to meet," "ongoing," "allowing," 
"launch," "addresses," "to work," "undertaking," "to develop," 
"investigating," "growing," "growth," "to support," "expected," "to be," 
"assume," "would," "estimates," "to advance," "to solidify," "committed, 
" "enabling" "to progress," "allowing," "anticipate," "pipelines," "to 
supplement," "investigational," "taking," "will," "estimated," "impact," 
"submissions," "focus," "launches," "innovation," "potential," "pipeline, 
" "priority," "outlook," "unforeseen," "forecast," "prevail," "enter," 
"to improve," "transformative," "manageable disruptions," "ongoing 
disruptions," "to delay," or similar expressions, or by express or 
implied discussions regarding potential new products, potential new 
indications for existing products, potential product launches, or 
regarding potential future revenues from any such products; or regarding 
the impact of the COVID-19 pandemic on certain therapeutic areas 
including dermatology, ophthalmology and the Sandoz retail business, and 
on drug development operations; or regarding potential future, pending 
or announced transactions; regarding potential future sales or earnings 
of the Group or any of its divisions; or by discussions of strategy, 
plans, expectations or intentions; or regarding the Group's liquidity or 

(MORE TO FOLLOW) Dow Jones Newswires

January 26, 2021 01:00 ET (06:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG 0.11% 79.88 Delayed Quote.-4.61%
TOTAL SE 1.11% 38.295 Real-time Quote.7.29%
All news about NOVARTIS AG
04/13ERASMUS UNIVERSITY ROTTERDAM : A bifurcated approach to labour market integratio..
AQ
04/13PRESS RELEASE  : Atriva Therapeutics Announces Changes to Management
DJ
04/13PRESS RELEASE : Evotec launches 'beLAB2122', translating academic innovation fro..
DJ
04/13PRESS RELEASE  : FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Inj..
DJ
04/12NOVARTIS  : Secures US FDA Nod for Xolair Prefilled Syringe for Self-Injection
MT
04/12NOVARTIS  : Roche's Genentech Gets FDA Nod for Xolair Prefilled Syringe for Self..
MT
04/12Novartis, Genentech Get FDA OK of Self-Administered Xolair
DJ
04/09NOVARTIS AG  : Receives a Sell rating from JP Morgan
MD
04/09PRESS RELEASE : Evotec and Exscientia announce start of human clinical trials of..
DJ
04/07IMMUTEP  : Gets European Patent Grant for LAG525 in Combination Therapy
MT
More news
Financials (USD)
Sales 2021 52 112 M - -
Net income 2021 10 103 M - -
Net Debt 2021 22 155 M - -
P/E ratio 2021 18,9x
Yield 2021 3,81%
Capitalization 196 B 195 B -
EV / Sales 2021 4,18x
EV / Sales 2022 3,90x
Nbr of Employees 105 794
Free-Float 85,6%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 105,93 $
Last Close Price 86,64 $
Spread / Highest target 71,9%
Spread / Average Target 22,3%
Spread / Lowest Target 3,87%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-4.61%195 170
JOHNSON & JOHNSON1.33%419 864
ROCHE HOLDING AG-0.95%285 584
PFIZER INC.0.43%207 285
MERCK & CO., INC.-6.56%193 467
ABBVIE INC.1.00%190 989